Radioactive tracers reveal Drug's journey in human body

NCT ID NCT07693218

Recruiting now Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This trial investigates how a new drug called BI 1815368 is absorbed, distributed, broken down, and eliminated from the body. Ten healthy men receive a single oral dose of the drug mixed with a radioactive tracer, plus a tiny intravenous dose of a different tracer. By measuring radioactivity in blood, urine, and stool, researchers can track the drug's path and determine its absolute bioavailability — how much of the oral dose reaches the bloodstream.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 1815368
What this could lead to: If successful, this trial will provide crucial data on how BI 1815368 behaves in the body, guiding future dosing and development for potential treatments.
What could go wrong: This is an early-phase study in only 10 healthy men, so results may not predict effects in patients. The use of radioactive tracers carries minimal radiation risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ICON-Groningen-62040
RECRUITING

Groningen, 9728 NZ, Netherlands

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.